FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 32350104 Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WEAVER GREGORY L			Requiring (Month/Da	2. Date of Event Requiring Statement (Month/Day/Year) 06/17/2021 3. Issuer Name and Ticker or Trading Symbol ATAI Life Sciences B.V. [ATAI]						
(Last)	(First)	(Middle)			4. Relationship of Reportin Issuer (Check all applicable)	,	F		5. If Amendment, Date of Original Filed (Month/Day/Year)	
KRAUSENSTRABE 9-10			_		Director Officer (give title below)	10% O Other (below)	specify 6. Ir	ndividual or Joint/Group Filing neck Applicable Line) Form filed by One Reporting		
(Street) BERLIN	2M	10117	_		Chief Financia	al Officer		X	Person	by More than One
(City)	(State)	(Zip)								
		Т	able I - No	n-Derivat	ive Securities Benefi	cially Ov	vned			
1. Title of Security (Instr. 4)					· • • • • • • • • • • • • • • • • • • •		rehin	t Ownership (Instr. 5)		
					Beneficially Owned (Instr. 4)	Form: D (D) or In	irect direct			
		(e. <u>ç</u>		Derivative	Beneficially Owned (Instr.	Form: D (D) or In (I) (Instr	ed	Owne		
1. Title of Der	rivative Securit			Derivative Ils, warra	Beneficially Owned (Instr. 4) e Securities Beneficia	Form: D (D) or In (I) (Instr ally Own tible sectorities	ed urities)	Sion	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr.
1. Title of Der	ivative Securi		J., puts, ca 2. Date Exerc Expiration Da	Derivative Ils, warra	Beneficially Owned (Instr. 4) Securities Beneficiants, options, convert 3. Title and Amount of Seunderlying Derivative Se	Form: D (D) or In (I) (Instr ally Own tible sectorities	ed urities)	Sion cise f	ership (Instr. ! 5. Ownership	6. Nature of Indirect Beneficial

Explanation of Responses:

1. The stock option vests as to 25% of the underlying shares on July 24, 2021, and the remaining underlying shares vest in 36 equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney.

/s/ Ryan Barrett, Attorney-06/17/2021

** Signature of Reporting

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by ATAI Life Sciences N.V. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

- execute for and on behalf of the undersigned, Schedules 13D and 13G in accordance with Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, and Forms 3, 4, and 5 in accordance with Section 16 of the Exchange Act and the rules thereunder;
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D or 13G or Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such schedule or form with the SEC and any stock exchange or similar authority; and
- 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Schedule 13D and 130 and Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of May, 2021.

Signature: /s/ Greg Weaver

Print Name: Greg Weaver

Schedule A

Individual Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

1. Ryan Barrett